Product Description: Gefitinib (ZD1839) (GMP) is Gefitinib (HY-50895) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Gefitinib is a potent, selective and orally active EGFR tyrosine kinase inhibitor[1][2].
Applications: Cancer-Kinase/protease
Formula: C22H24ClFN4O3
References: [1]Wakeling AE, et al. ZD1839: an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 2002 Oct 15;62(20):5749-54. /[2]Liu X, Li C, et al. EGF signaling promotes the lineage conversion of astrocytes into oligodendrocytes. Mol Med. 2022 May 4;28(1):50. /[3]Ware KE, et al. A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop. Oncogenesis. 2013 Mar 25;2(3):e39.
CAS Number: 184475-35-2
Molecular Weight: 446.90
Research Area: Cancer
Solubility: 10 mM in DMSO
Target: Apoptosis;Autophagy;EGFR
English
Deutsch
